Diplomat Pharmacy (DPLO) Tops Q2 EPS by 4c; Raises Outlook

Diplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.16, $0.04 better than the analyst estimate of $0.12. Revenue for the quarter came in at $808 million versus the consensus estimate of $738.99 million.

Diplomat Pharmacy sees FY2015 EPS of $0.56-$0.60, versus prior guidance of $0.48-$0.51 and the consensus of $0.59. Diplomat Pharmacy sees FY2015 revenue of $3.2-3.4 million, versus prior guidance of $2.9-3.1 million and the consensus of $3.24 million.

Phil Hagerman, Chairman and CEO of Diplomat, commented, "This was another great quarter for Diplomat. We saw strong performance across the entire company as we continued to capitalize on our role as the nation's largest independent specialty pharmacy. We continued to integrate our previously acquired specialty infusion entities and, in an effort to expand our hepatitis C capabilities, we acquired Burman's Specialty Pharmacy in June. The acquisition, including use of Burmans' proprietary technology, will allow us to more deeply penetrate the hepatitis C market across the Diplomat enterprise. As a result of our solid financial results in the quarter, we are also raising our 2015 financial outlook."

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery